<div id="readability-page-1">The deal grants Genentech exclusive global rights to develop and commercialise the selected RNAi programme.According to the contract, SanegeneBio will manage early development activities while Genentech will assume responsibility for all subsequent clinical development and global commercialisation.The collaboration centres on SanegeneBio’s RNAi platform, which features new chemistries and delivery technologies designed to generate small interfering ribonucleic acid (siRNA) medicines targeting multiple disease areas.The deal provides SanegeneBio with an upfront payment of $200m. Additionally, the company is eligible for development and commercialisation milestone payments that total up to $1.5bn, alongside tiered royalties based on future product sales.SanegeneBio CEO and founder Weimin Wang said: “Entering into this agreement with Genentech marks another important milestone for our innovative and differentiated RNAi chemistry and delivery platforms. We are delighted to work with a global scientific leader to continue delivering effective and life-changing therapies for patients worldwide.”SanegeneBio operates as a venture-backed biotechnology company focused on advancing RNAi-based therapeutics. The company’s research and development (R&amp;D) presence spans Shanghai, Suzhou, and Boston.Its development pipeline includes experimental medicines addressing cardiometabolic indications, obesity, and autoimmune nephropathies. The company has already initiated clinical trials for four experimental medicines targeting these areas, utilising its LEAD tissue-selective RNAi delivery technology.In November 2025, SanegeneBio formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi candidates for metabolic diseases.The post SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal appeared first on Pharmaceutical Business review.</div>

SanegeneBio has signed a $1.5bn global licensing deal with Genentech, granting exclusive rights to develop and commercialize its RNAi programme. The agreement includes a $200m upfront payment and potential milestone payments up to $1.5bn, along with tiered royalties on future sales. SanegeneBio will manage early development, while Genentech will handle clinical development and commercialization. This partnership aims to leverage SanegeneBio's innovative RNAi technology for various disease treatments.

Pharmaceutical Business Review

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ark Genomic Revolution ETF

ChinaAMC SSE Health Care ETF Initiating Fund

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Hwabao WP CSI Medical Service ETF

CS精准医

Bosera Hang Seng Health Care ETF(QDII)

VG Health

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

ChinaAMC CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bionano Genomics

Minsheng Royal CSI Biotechnology Theme ETF

Niagen Bioscience

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

SPDR S&P Health Equip

Yinhua CSI Innovative Drugs Industry ETF

Roche

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI 300 Health Care ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

iShares Global Healthcare

iShares US Medical Devices

ChinaAMC SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

iShares Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

Sesen Bio, Inc.

Invesco Biotechnology & Genome ETF

SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal